ASCO 2017 | The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers
Howard A. Burris, MD, FASCO from the Sarah Cannon Research Institute, Nashville, TN discusses the TRK inhibitor LOXO-101 (larotrectinib) and its impact on patients with TRK fusion cancers (NCT02576431, NCT02122913, NCT02637687). Dr Burris emphasizes that this highlights the importance of looking at the molecular profile of patients.
This interview was recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.
Get great new content delivered to your inboxSign up